HDAC9 and mantle cell lymphoma: Beside HDAC and bromodomain inhibition, cladribine, a hypomethylating agent that indirectly downregulates DNA methylation, has been used with vorinostat and rituximab in a phase 1/2 trial involving both naïve and R/R MCL patients.